Skip to main content
Premium Trial:

Request an Annual Quote

RxGen Opens Toxicology Subsidiary, Names Unit CEO

NEW YORK, Jan. 26 (GenomeWeb News) - RxGen today said it has created RxGen PrimaTox, a wholly owned subsidiary focused on drug-safety products and services.


RxP is developing drug safety biomarkers using "tox-omics" tools and will provide these as stand-alone products. It is also building a primate-based molecular toxicology database to be available on a subscription basis, the company said.


Spencer Farr, founder of Xenometrix and Phase-1 Toxicology, was named CEO of the new unit.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.